Special lenses may curb worsening nearsightedness in kids

NCT ID NCT07698977

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether D.I.M.S. glasses, which have special lenslets that create blur in the peripheral vision, can slow the progression of myopia (nearsightedness) in children aged 6 to 15. Participants wear the glasses while awake and visit the clinic every six months for eye exams and measurements of eye length. The researchers also track time spent outdoors and screen time to see if these factors affect myopia progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
D.I.M.S. (Defocus Incorporated Multiple Segments) glasses
What this could lead to
If successful, this could provide a non-invasive way to slow myopia progression in children, reducing the need for stronger prescriptions and lowering the risk of severe eye problems later in life.
What could go wrong
This is a small observational study, not a randomized trial, so results may not apply to all children. The glasses may not work for everyone, and long-term effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Semmelweis University Ophthalmology Department

    RECRUITING

    Budapest, 1085, Hungary

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.